This study examines the effect of muscimol, a high affinity, specific gamma-aminobutyric acid (GABA) agonist, on glucose-stimulated somatostatin and insulin release from the isolated, perfused rat pancreas. Perfusion with low glucose (50 mg/dl) conditions resulted in basal somatostatin release of 46 ± 4 pg/ml. Basal insulin release was less than 20 /u,U/ml. High glucose (300 mg/dl) conditions stimulated somatostatin and insulin release. Steady-state levels of somatostatin and insulin release under high glucose conditions were 425 ± 1 2 pg/ml and 419 ± 18 /xU/ml, respectively. Perfusion with medium containing 1 /u.M muscimol inhibited glucose-stimulated somatostatin release by 38%, whereas the course of glucose-stimulated insulin release was unaffected. Tentative conclusions from this study are (1) that GABA is potentially a modulator of islet somatostatin but not insulin release, and (2) the fact that somatostatin, an inhibitor of insulin, can be suppressed 38% without coincidental increase in insulin release seems to indicate that, under high glucose conditions, somatostatih is without a significant paracrine effect on the beta-cells. DIABETES 30:168-171, February 1981. Recently, GABA has been found in a variety of tissues outside of the CNS, with its highest concentration localized in the islet of Langerhans. cretion. Muscimol, a high affinitiy, specific GABA agonist 4 was used in this study to elucidate a potential effect of GABA on pancreatic hormone secretion.
G amma-aminobutyric acid (GABA) is a putative neurotransmitter in the central nervous system. 1 Recently, GABA has been found in a variety of tissues outside of the CNS, with its highest concentration localized in the islet of Langerhans.
2 -3 Localization of GABA within the islet of Langerhans suggests that GABA may play a role in modulating the endocrine pancreas. 3 This study was undertaken to determine what function GABA may have in modulating pancreatic hormone se-
MATERIALS AND METHODS
Pancreata from fasted, anesthetized male Sprague-Dawley rats (150-200 g) were perfused according to the procedure of Loubatieres et al., 5 as modified by Sorenson et al. 6 The perfusion medium consisted of Krebs bicarbonate balanced salt solution containing 0.25% bovine serum albumin (Armour), 20 mM Hepes (pH 7.2), 10 mg/dl soybean trypsin inhibitor (Sigma, type 1-s), and 3.8% dextran (Sigma). The medium was maintained at 37°C and perfused with a Gilson Minipuls 2 pump at a rate of 1.2 ml/min. Pancreata were maintained at 37°C in a water-jacketed tissue chamber. Fractions were collected at 2-min intervals.
Pancreata were perfused with medium containing 50 mg/dl glucose for 20 min before beginning the experiment. The control protocol was to perfuse with medium containing 50 mg/dl glucose for 10 min, 300 mg/dl glucose for 60 min, and 50 mg/dl glucose for 14 min. Steady-state values for somatostatin and insulin release from control experiments were calculated by averaging their mean concentrations in the effluent from 30 to 40 min after initiating perfusion with 300 mg/dl glucose. This time period corresponded with the last 10 min of perfusion with medium containing 1 /JLM muscimol in the experimental protocol. The experimental protocol was to perfuse with medium containing 50 mg/dl glucose for 10 min, 30 mg/dl glucose for 20 min, 300 mg/dl glucose and 1 /nM muscimol for 20 min, 300 mg/dl glucose for 20 min, and 50 mg/dl glucose for 14 min. The average concentrations of somatostatin and insulin released into the effluent during the five treatment groups were calculated by averaging the mean release concentrations for the last 10 min of each treatment. Neutral red was added to the medium at the end of the experiment to verify that the tissue had been adequately perfused throughout the procedure.
Immunoreactive insulin 7 and somatostatin 8 concentrations in the perfusate were determined by radioimmunoassay as previously described. 9 Subsequent use of the terms "insulin" and "somatostatin" refers to the immunoreactive peptides. Aliquots of 50 /ul for insulin and 250 /u.l for somatostatin were assayed in each fraction. Results were calculated using a Hewlett-Packard Computer System 9845 B. A Spline curve fit was used for all graphics. Variation of the means for replicated experiments are reported as the standard errors. Statistical differences between means were determined using a one way analysis of variance and Duncan's new multiple range test. 
(62) (77) -* Represents significant difference in somatostatin release than observed during initial perfusion with 50 mg/dl glucose (P < 0.01). t Represents significant difference in somatostatin release than observed during initial perfusion with 300 mg/dl glucose (P < 0.01). $ Represents significant difference in somatostatin release than observed during perfusion with medium containing 1 /xM muscimol (P < 0.05).
RESULTS
Effect of muscimol on pancreatic somatostatin and insulin release. Perfusion of pancreata with medium containing 300 mg/dl glucose resulted in a significant stimulation of somatostatin release ( Figure 1 ). Addition of 1 /AM muscimol to the perfusion medium resulted in a significant depression of glucose-stimulated somatostatin release. An incomplete recovery in somatostatin release was observed after discontinuing perfusion with muscimol-containing medium. The average concentration of somatostatin released into the perfusate during the five treatment groups is shown in Table 1 . Basal somatostatin release was 46 ± 4 pg/ml. Perfusion of pancreata with 300 mg/dl glucose resulted in a 9-fold increase in somatostatin release (407 ± 25 pg/ml). Muscimol inhibited somatostatin release by 38% (252 ± 3 pg/ml). Somatostatin release returned to 77% of its initial glucose-stimulated level after muscimol was removed from the perfusion medium. In control (N = 6, data not shown) and experimental protocols, a steady-state level of somatostatin release was attained after 10 min of glucose stimulation. However, in the control experiments the course of somatostatin release remained unchanged (425 ± 12 pg/ml) throughout the glucose stimulation period. Perfusion of pancreata with 300 mg/dl glucose resulted in a significant stimulation of insulin release (Figure 2 ). Addition of 1 /xM muscimol to the perfusion medium had no ef- feet on the course of insulin release. In control (N = 6, data not shown) and experimental protocols, a steady-state level of insulin release was attained after 20 min of glucose stimulation. Mean insulin release during the period of glucose stimulation in control and experimental protocols were 419 ± 18 /ull/ml and 400 ± 8 /xU/ml, respectively. No differences were observed in the course of insulin release from control and experimental protocols.
Comparison of the release profiles of somatostatin and insulin reveals an apparent dissociation in somatostatin and insulin release (Figure 3) . Initiation of somatostatin release after glucose stimulation was consistently delayed with respect to the initiation of insulin release. Somatostatin release attained a steady-state level after 10 min of glucose stimulation, whereas insulin release reached a steady-state level after 20 min of glucose stimulation. Muscimol inhibited glucose-stimulated somatostatin release by 38% without altering the course of insulin release. These results demonstrate that somatostatin release can be altered without affecting insulin release under conditions of high glucose.
DISCUSSION
Muscimol, a high affinity, specific GABA agonist, 4 inhibited glucose-stimulated pancreatic somatostatin release, but had no effect on glucose-stimulated insulin release. After 10 min of glucose stimulation, somatostatin release achieved a steady-state level that was maintained throughout the period of glucose stimulation. Perfusion with 1 fiM muscimol in the presence of high glucose caused a significant inhibition of somatostatin release. After discontinuing perfusion with muscimol, somatostatin release did not return to initial steady-state levels, indicating that the inhibitory effect was not completely reversed by perfusion with 300 mg/dl glucose. Insulin release from glucose-stimulated pancreata achieved a steady-state level after 20 min and was maintained throughout the period of glucose stimulation. No differences in the insulin release profiles from control and experimental protocols were observed, indicating that muscimol did not alter the course of insulin release.
Pancreata were perfused with 1 /xM muscimol at a rate of 1.2 ml/min, which corresponds to exposing the pancreas to approximately 1 nmol muscirhol/g wet wt./min. Recently, it has been reported that the pancreas contains approximately 40 nmol GABA/g wet wt. 3 It is reasonable that the delta-cell may be exposed to these concentrations of GABA in vivo, since the majority of the pancreatic GABA is localized in the isiet. Based on these calculations, it appears that GABA, under normal physiologic conditions, is present in the pancreas in sufficient concentrations to inhibit somatostatin release. In addition, circulating GABA concentrations may play a role in regulating pancreatic somatostatin release, since rat blood contains approximately 0.8 nmol GABA/ml. 10 It has been suggested that pancreatic somatostatin may act directly on the pancreas by regulating glucagon and insulin release. 11 Numerous investigators have demonstrated that exogenous somatostatin inhibits glucagon and insulin release in vitro.
12 " 14 Previous studies in our laboratory have questioned the physiologic significance of pancreatic somatostatin in modulating insulin release under high glucose conditions. 6 The observation that 1 /xM muscimol suppressed pancreatic somatostatin release by 38% without altering glucose-stimulated insulin release supports the hypothesis that, under conditions of high glucose, pancreatic somatostatin may not exert a paracrine effect on insulin release. Gerber and Hare 3 have suggested that GABA may act as a local regulator in the endocrine pancreas. The physiologic conditions in which somatostatin and GABA may act as regulators of pancreatic hormone release need to be more closely defined.
The purpose of this study was to determine the role of pancreatic GABA in regulating hormone release. Tentative conclusions from this study are that GABA potentially modulates islet somatostatin release and that, under conditions of high glucose, somatostatin may not exert a paracrine effect oh insulin release.
